Progenics Pharmaceuticals Company Profile (NASDAQ:PGNX)

About Progenics Pharmaceuticals

Progenics Pharmaceuticals logoProgenics Pharmaceuticals, Inc. is engaged in developing medicines and other products for targeting and treating cancer. The Company's products in development include therapeutic agents designed to target cancer and imaging agents, which focuses on enabling clinicians and patients to accurately visualize and manage their diseases. The Company's EXINI Bone BSI is an analytical tool that employs an artificial intelligence-based approach to apply techniques of statistical analysis and pattern recognition to quantify the information produced by bone scintigraphy (bone scan) images used to view cancer present in the skeleton. The EXINI Bone BSI tool reads bone scans and produces an automated Bone Scan Index quantification. The Company's clinical-stage products include AZEDRA, 1404 (trofolastat), PyL ([18F] DCFPyL), 1095 and PSMA ADC. The Company's partnered products include Relistor-Subcutaneous injection, Relistor-Oral Tablets and PRO 140.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: PGNX
  • CUSIP: 74318710
Key Metrics:
  • Previous Close: $10.36
  • 50 Day Moving Average: $9.35
  • 200 Day Moving Average: $7.62
  • 52-Week Range: $70,051,000.00 - $3.80
  • Trailing P/E Ratio: 66.84
  • Foreward P/E Ratio: -23.02
  • P/E Growth: 0.49
  • Market Cap: $725.73M
  • Outstanding Shares: 70,051,000
  • Beta: 3.11
Profitability:
  • Net Margins: 15.55%
  • Return on Equity: 12.27%
  • Return on Assets: 8.24%
Debt:
  • Current Ratio: 7.71%
  • Quick Ratio: 7.71%
Additional Links:
Companies Related to Progenics Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Progenics Pharmaceuticals (NASDAQ:PGNX) (?)
Ratings Breakdown: 4 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 3.20)
Consensus Price Target: $11.60 (11.97% upside)

Analysts' Ratings History for Progenics Pharmaceuticals (NASDAQ:PGNX)
Show:
DateFirmActionRatingPrice TargetDetails
2/6/2017Needham & Company LLCUpgradeBuy -> Strong-Buy$11.00 -> $14.00View Rating Details
1/10/2017Jefferies Group LLCSet Price TargetBuy$9.00 -> $11.00View Rating Details
11/30/2016BTIG ResearchBoost Price TargetBuy$9.00 -> $11.00View Rating Details
11/8/2016AegisReiterated RatingBuy$11.00View Rating Details
10/4/2016Brean CapitalInitiated CoverageBuy$11.00View Rating Details
(Data available from 2/26/2015 forward)

Earnings

Earnings History for Progenics Pharmaceuticals (NASDAQ:PGNX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/9/2017        
11/7/2016Q316$0.55$0.52$52.90 million$53.90 millionViewListenView Earnings Details
8/4/2016Q216($0.13)($0.08)$6.33 million$8.50 millionViewN/AView Earnings Details
5/5/2016Q116($0.13)($0.18)$3.27 million$2.50 millionViewListenView Earnings Details
3/11/2016Q415($0.14)($0.10)$2.25 million$5.10 millionViewListenView Earnings Details
11/9/2015Q315($0.13)($0.14)$2.35 million$1.40 millionViewListenView Earnings Details
8/6/2015Q215($0.15)($0.17)$1.63 million$1.90 millionViewListenView Earnings Details
5/6/2015Q115($0.16)($0.15)$1.30 million$0.25 millionViewN/AView Earnings Details
3/16/2015Q414($0.13)($0.18)$2.87 million($0.57) millionViewN/AView Earnings Details
11/7/2014Q314($0.16)$0.51$2.50 million$41.66 millionViewN/AView Earnings Details
8/8/2014Q214($0.14)($0.17)$2.83 million$1.50 millionViewListenView Earnings Details
5/9/2014Q114($0.15)($0.15)$2.88 million$1.80 millionViewN/AView Earnings Details
3/13/2014Q4($0.19)($0.14)$1.48 million$3.00 millionViewListenView Earnings Details
11/11/2013Q313($0.22)($0.17)$2.00 million$0.90 millionViewN/AView Earnings Details
8/9/2013Q2 2013($0.24)($0.24)$1.86 million$1.80 millionViewN/AView Earnings Details
5/10/2013Q1 2013($0.19)($0.22)$1.71 million$2.23 millionViewN/AView Earnings Details
3/15/2013Q4 2012($0.31)($0.01)$1.16 million$8.87 millionViewN/AView Earnings Details
11/8/2012Q312($0.30)($0.33)$2.52 million$1.10 millionViewN/AView Earnings Details
8/9/2012($0.32)($0.32)ViewN/AView Earnings Details
5/8/2012($0.33)($0.39)ViewN/AView Earnings Details
11/9/2011($0.33)($0.34)ViewN/AView Earnings Details
8/9/2011($0.25)$1.64ViewN/AView Earnings Details
5/10/2011($0.51)($0.69)ViewN/AView Earnings Details
3/15/2011($0.57)($0.57)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Progenics Pharmaceuticals (NASDAQ:PGNX)
Current Year EPS Consensus Estimate: $0.07 EPS
Next Year EPS Consensus Estimate: $-0.45 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.12)($0.12)($0.12)
Q2 20161($0.11)($0.11)($0.11)
Q3 20161$0.51$0.51$0.51
Q4 20161($0.22)($0.22)($0.22)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Progenics Pharmaceuticals (NASDAQ:PGNX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Progenics Pharmaceuticals (NASDAQ:PGNX)
Insider Ownership Percentage: 5.48%
Institutional Ownership Percentage: 85.95%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/15/2017Healthcare Master Fun BroadfinMajor ShareholderSell602,600$9.66$5,821,116.00View SEC Filing  
2/9/2017Healthcare Master Fun BroadfinMajor ShareholderSell351,300$9.71$3,411,123.00View SEC Filing  
6/11/2015Robert J IsraelEVPSell2,000$6.83$13,660.00View SEC Filing  
3/13/2015Robert J IsraelEVPSell3,000$7.00$21,000.00View SEC Filing  
3/11/2015Robert J IsraelEVPSell2,000$6.83$13,660.00View SEC Filing  
3/3/2015Robert J IsraelEVPSell5,000$6.49$32,450.00View SEC Filing  
1/12/2015Robert J IsraelEVPSell2,000$7.06$14,120.00View SEC Filing  
12/11/2014Robert J IsraelEVPSell3,000$7.07$21,210.00View SEC Filing  
11/21/2014Robert J IsraelEVPSell9,000$7.00$63,000.00View SEC Filing  
11/13/2014Robert J IsraelEVPSell10,000$6.83$68,300.00View SEC Filing  
11/11/2014Robert J IsraelEVPSell5,000$6.53$32,650.00View SEC Filing  
7/21/2014Healthcare Master Fun BroadfinMajor ShareholderBuy1,625,436$4.60$7,477,005.60View SEC Filing  
7/18/2014Healthcare Master Fun BroadfinMajor ShareholderBuy388,200$4.73$1,836,186.00View SEC Filing  
7/17/2014Healthcare Master Fun BroadfinMajor ShareholderBuy436,884$4.48$1,957,240.32View SEC Filing  
7/16/2014Healthcare Master Fun BroadfinMajor ShareholderBuy411,693$4.48$1,844,384.64View SEC Filing  
7/18/2013Robert J IsraelVPSell5,000$6.33$31,650.00View SEC Filing  
2/27/2013Mark Robert BakerCEOBuy1,262$2.72$3,432.64View SEC Filing  
1/22/2013Mark Robert BakerCEOBuy1,215$2.82$3,426.30View SEC Filing  
12/26/2012Mark Robert BakerCEOBuy1,142$3.01$3,437.42View SEC Filing  
11/28/2012Mark Robert BakerCEOBuy1,607$2.13$3,422.91View SEC Filing  
11/19/2012Mark Robert BakerCEOBuy11,800$1.96$23,128.00View SEC Filing  
11/16/2012Mark Robert BakerCEOBuy49,793$1.82$90,623.26View SEC Filing  
11/15/2012Mark Robert BakerCEOBuy48,833$1.69$82,527.77View SEC Filing  
10/24/2012Mark Robert BakerCEOBuy1,162$2.96$3,439.52View SEC Filing  
9/26/2012Mark Robert BakerCEOBuy1,036$3.32$3,439.52View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Progenics Pharmaceuticals (NASDAQ:PGNX)
DateHeadline
News IconProgenics Pharmaceuticals Inc. (PGNX) Stock Rating Upgrade by ... - Petro Global News 24 (NASDAQ:PGNX)
petroglobalnews24.com - February 26 at 12:01 PM
News IconStock Update for Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX ... - Midway Monitor (NASDAQ:PGNX)
midwaymonitor.com - February 25 at 1:20 AM
News IconThe Key Figures To Watch From Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Earnings (NASDAQ:PGNX)
latribunadecanarias.com - February 24 at 8:18 PM
finance.yahoo.com logoProgenics Pharmaceuticals Sets Fourth Quarter and Year-End 2016 Financial Results Call for March 9 (NASDAQ:PGNX)
finance.yahoo.com - February 23 at 9:01 AM
News IconFrance training 'drone-hunting-eagles' amid fears of possible terror (NASDAQ:PGNX)
ekosvoice.com - February 22 at 7:20 PM
News IconStock Spotlight: Zooming in on Shares of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) - BVN (NASDAQ:PGNX)
bvnewsjournal.com - February 22 at 9:16 AM
seekingalpha.com logoProgenics: A Look At Upcoming Adreza Data - Seeking Alpha (NASDAQ:PGNX)
seekingalpha.com - February 22 at 9:16 AM
News IconEquity Perception: Analyst's Indicator Review for Progenics Pharmaceuticals, Inc. (PGNX), Whiting Petroleum ... - The USA Commerce (NASDAQ:PGNX)
theusacommerce.com - February 22 at 9:16 AM
News IconProgenics Pharmaceuticals Inc. (NASDAQ:PGNX) Broker Views On Wall Street (NASDAQ:PGNX)
techknowbits.com - February 18 at 6:21 PM
News IconTechnical Study: Following Indicators for Progenics Pharmaceuticals Inc. (PGNX) - Baldwin Journal (NASDAQ:PGNX)
baldwinjournal.com - February 18 at 11:37 AM
News IconProgenics Pharmaceuticals, Inc. (PGNX): The Technicals As Seen Today - NY Stock News (NASDAQ:PGNX)
nystocknews.com - February 18 at 11:37 AM
News IconThe Research Analysts' Weekly Ratings Updates for Progenics Pharmaceuticals (PGNX) (NASDAQ:PGNX)
mundoaguaysaneamiento.net - February 16 at 11:51 PM
istreetwire.com logoMomentum Stocks: Progenics Pharmaceuticals, Inc. (PGNX), The WhiteWave Foods Company (WWAV), The Medicines ... - iStreetWire (NASDAQ:PGNX)
istreetwire.com - February 16 at 6:49 PM
streetinsider.com logoProgenics Pharma (PGNX) Begins Phase 1 Trial of its PSMA-Targeted Therapeutic Candidate 1095 ForTreatment of ... - StreetInsider.com (NASDAQ:PGNX)
www.streetinsider.com - February 16 at 6:49 PM
News IconProgenics Pharmaceuticals, Inc. (PGNX) Analyst Opinion And Outlook - Post Analyst (NASDAQ:PGNX)
postanalyst.com - February 16 at 6:49 PM
streetinsider.com logoProgenics Pharmaceuticals (PGNX) and Shutterfly (SFLY) to Join ... - StreetInsider.com (NASDAQ:PGNX)
www.streetinsider.com - February 16 at 6:49 PM
thestreet.com logoBiotech Premarket Movers: Progenics, Alexion, BioCryst (NASDAQ:PGNX)
www.thestreet.com - February 16 at 6:49 PM
finance.yahoo.com logoProgenics Pharmaceuticals Announces Initiation of a Phase 1 Clinical Trial of its PSMA-Targeted Therapeutic Candidate 1095 For the Treatment of Metastatic Prostate Cancer (NASDAQ:PGNX)
finance.yahoo.com - February 14 at 11:24 PM
News IconTicker Tracker: Looking at Progenics Pharmaceuticals Inc. (PGNX) - Rives Journal (NASDAQ:PGNX)
rivesjournal.com - February 10 at 2:18 AM
bizjournals.com logoTechnical Reports on Biotech Stocks -- Progenics Pharma, Intrexon, Synthetics Biologics, and 22nd Century (NASDAQ:PGNX)
www.bizjournals.com - February 9 at 9:18 PM
globenewswire.com logoProgenics Pharmaceuticals, Inc. to Participate in February Investor Conferences - GlobeNewswire (press release) (NASDAQ:PGNX)
globenewswire.com - February 9 at 1:13 AM
finance.yahoo.com logoProgenics Pharmaceuticals, Inc. to Participate in February Investor Conferences (NASDAQ:PGNX)
finance.yahoo.com - February 8 at 8:10 PM
finance.yahoo.com logoProgenics Pharm upgraded by Needham (NASDAQ:PGNX)
finance.yahoo.com - February 6 at 7:20 PM
4-traders.com logoPROGENICS PHARMACEUTICALS INC : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K) (NASDAQ:PGNX)
www.4-traders.com - January 30 at 7:51 PM
capitalcube.com logoProgenics Pharmaceuticals, Inc. – Value Analysis (NASDAQ:PGNX) : January 30, 2017 (NASDAQ:PGNX)
www.capitalcube.com - January 30 at 7:51 PM
News IconInvestor Technical Review for Progenics Pharmaceuticals Inc. (PGNX) - Rives Journal (NASDAQ:PGNX)
rivesjournal.com - January 30 at 8:33 AM
capitalcube.com logoProgenics Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : PGNX-US : January 27, 2017 (NASDAQ:PGNX)
www.capitalcube.com - January 28 at 5:40 AM
News IconProgenics Pharmaceuticals Inc. (NASDAQ:PGNX) Daily Sentiment Score At 0.418 - Stock Observer (NASDAQ:PGNX)
www.thestockobserver.com - January 26 at 5:38 AM
News IconTrading Scope: Following Levels on Shares of Progenics Pharmaceuticals Inc. (PGNX) - Sherwood Daily (NASDAQ:PGNX)
sherwooddaily.com - January 23 at 12:02 AM
marketnewsvideo.com logoCommit To Buy Progenics Pharmaceuticals At $7, Earn 12.9% Using Options (NASDAQ:PGNX)
www.marketnewsvideo.com - January 21 at 1:05 AM
News IconInvesting Focus: Indicators in View on Shares of Progenics Pharmaceuticals Inc. (PGNX) - Rives Journal (NASDAQ:PGNX)
rivesjournal.com - January 20 at 8:04 PM
capitalcube.com logoETFs with exposure to Progenics Pharmaceuticals, Inc. : January 20, 2017 (NASDAQ:PGNX)
www.capitalcube.com - January 20 at 8:04 PM
News IconProgenics Pharmaceuticals Inc. (NASDAQ:PGNX) Daily Sentiment Score At 0.56 - Stock Observer (NASDAQ:PGNX)
www.thestockobserver.com - January 18 at 12:38 AM
News IconProgenics Pharmaceuticals Inc PGNX Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:PGNX)
www.bioportfolio.com - January 16 at 10:51 AM
News IconStock Getting Tripped Up In Session: Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) - Wall Street Beacon (NASDAQ:PGNX)
wsbeacon.com - January 11 at 7:50 PM
News IconProgenics Pharmaceuticals Inc. (NASDAQ:PGNX) Daily Sentiment Score At 0.197 - Stock Observer (NASDAQ:PGNX)
www.thestockobserver.com - January 11 at 1:08 AM
marketexclusive.com logoProgenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Files An 8-K Entry into a Material Definitive Agreement (NASDAQ:PGNX)
marketexclusive.com - January 9 at 7:52 PM
biz.yahoo.com logoPROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements an (NASDAQ:PGNX)
biz.yahoo.com - January 9 at 7:52 PM
thestreet.com logoMy Top 2017 Pick: Progenics Pharmaceuticals (NASDAQ:PGNX)
realmoney.thestreet.com - January 3 at 11:53 PM
News IconLevels in View for Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) - Wall Street Beacon (NASDAQ:PGNX)
wsbeacon.com - December 30 at 7:33 PM
News IconBearish Target Of Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) At $9 - Stock Observer (NASDAQ:PGNX)
www.thestockobserver.com - December 29 at 7:12 PM
rttnews.com logoProgenics Pharmaceuticals Inc. (PGNX) Is Up After Committee Review - RTT News (NASDAQ:PGNX)
www.rttnews.com - December 23 at 6:30 AM
streetinsider.com logoProgenics Pharma (PGNX) Says DMC Recommends Phase 3 Clinical Trial of SPECT/CT Imaging Agent 1404 Continue (NASDAQ:PGNX)
www.streetinsider.com - December 23 at 12:32 AM
News IconProgenics Pharma (PGNX) Gets Go-Ahead Recommendation; Mizuho Eyeing Opportunity in Sucampo Pharma (SCMP) (NASDAQ:PGNX)
galaxystocks.com - December 23 at 12:32 AM
rttnews.com logoProgenics Pharmaceuticals Inc. (PGNX) Is Up After Committee Review (NASDAQ:PGNX)
www.rttnews.com - December 22 at 7:31 PM
finance.yahoo.com logoProgenics Pharmaceuticals Announces Independent Committee’s Positive Recommendation for Continuation of Phase 3 Clinical Trial of SPECT/CT Imaging Agent 1404 (NASDAQ:PGNX)
finance.yahoo.com - December 22 at 7:31 PM
finance.yahoo.com logo4:17 pm Progenics Pharm announces Independent Committee's positive recommendation for continuation of Phase 3 clinical trial of SPECT/CT imaging agent 1404; mofification proposed by co agreed to by the FDA (NASDAQ:PGNX)
finance.yahoo.com - December 22 at 7:31 PM
publicnow.com logoProgenics Pharmaceuticals Announces Independent Committee's Positive Recommendation for Continuation of Phase 3 Clinical Trial of SPECT/CT Imaging Agent 1404 (NASDAQ:PGNX)
www.publicnow.com - December 22 at 7:31 PM
marketwatch.com logoProgenics shares rally as prostate cancer imaging study to continue (NASDAQ:PGNX)
www.marketwatch.com - December 22 at 7:31 PM
investornewswire.com logoSentiments And Ratings Alert: Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) - Investor Newswire (NASDAQ:PGNX)
www.investornewswire.com - December 20 at 1:42 PM

Social

What is Progenics Pharmaceuticals' stock symbol?

Progenics Pharmaceuticals trades on the NASDAQ under the ticker symbol "PGNX."

Where is Progenics Pharmaceuticals' stock going? Where will Progenics Pharmaceuticals' stock price be in 2017?

5 analysts have issued twelve-month price objectives for Progenics Pharmaceuticals' stock. Their predictions range from $11.00 to $14.00. On average, they anticipate Progenics Pharmaceuticals' stock price to reach $11.60 in the next twelve months.

When will Progenics Pharmaceuticals announce their earnings?

Progenics Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March, 9th 2017.

What are analysts saying about Progenics Pharmaceuticals stock?

Here are some recent quotes from research analysts about Progenics Pharmaceuticals stock:

  • Needham & Company LLC analysts commented, "We recently chose PGNX as our Top Pick for 2017 and are now going one step further and upgrading it to Strong Buy. We continue to expect significant appreciation in shares this year as the company launches its first wholly owned product and moves rapidly toward profitability. Our increased $14 price target reflects the introduction of estimates for the 1404 imaging agent, which recently passed an interim analysis in its pivotal trial." (2/6/2017)
  • According to Zacks Investment Research, "Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics' first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic in a two-cohort phase 2 clinical trial and a small molecule imaging agent that has completed patient dosing in a phase 2 trial. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra(TM), an ultra-orphan radiotherapy candidate also in a phase 2 study under an SPA. Progenics' first commercial product, Relistor(R) (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Inc. " (1/10/2017)

Who owns Progenics Pharmaceuticals stock?

Progenics Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Federated Investors Inc. PA (17.54%), Broadfin Capital LLC (12.78%), FMR LLC (5.11%), Pinnacle Associates Ltd. (3.80%), State Street Corp (2.94%) and Royce & Associates LP (2.08%). Company insiders that own Progenics Pharmaceuticals stock include Healthcare Master Fun Broadfin and Robert J Israel.

Who sold Progenics Pharmaceuticals stock? Who is selling Progenics Pharmaceuticals stock?

Progenics Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Federated Investors Inc. PA, Royce & Associates LP, Dimensional Fund Advisors LP, Pinnacle Associates Ltd., Cadence Capital Management LLC, Turner Investments LLC and Ellington Management Group LLC.

Who bought Progenics Pharmaceuticals stock? Who is buying Progenics Pharmaceuticals stock?

Progenics Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Oxford Asset Management, FMR LLC, Bogle Investment Management L P DE, Pacad Investment Ltd., State Board of Administration of Florida Retirement System, GSA Capital Partners LLP and Dynamic Technology Lab Private Ltd.

How do I buy Progenics Pharmaceuticals stock?

Shares of Progenics Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Progenics Pharmaceuticals stock cost?

One share of Progenics Pharmaceuticals stock can currently be purchased for approximately $10.36.

Progenics Pharmaceuticals (NASDAQ:PGNX) Chart for Sunday, February, 26, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Progenics Pharmaceuticals (NASDAQ:PGNX)

Earnings History Chart

Earnings by Quarter for Progenics Pharmaceuticals (NASDAQ:PGNX)

Dividend History Chart

Dividend Payments by Quarter for Progenics Pharmaceuticals (NASDAQ:PGNX)

Last Updated on 2/26/2017 by MarketBeat.com Staff